In 2020, the FDA declared that patients with unresectable malignant pleural mesothelioma (MPM), and NSCLC (with tumor PD-L1 expression ≥ 1% and without EGFR/ALK alterations) can benefit from treatment with Opdivo (Nivolumab) plus Yervoy (Ipilimumab) as a first-line treatment [41]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.